1. Home
  2. STVN vs JAZZ Comparison

STVN vs JAZZ Comparison

Compare STVN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • JAZZ
  • Stock Information
  • Founded
  • STVN 1949
  • JAZZ 2003
  • Country
  • STVN Italy
  • JAZZ Ireland
  • Employees
  • STVN N/A
  • JAZZ N/A
  • Industry
  • STVN Containers/Packaging
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • JAZZ Health Care
  • Exchange
  • STVN Nasdaq
  • JAZZ Nasdaq
  • Market Cap
  • STVN 5.7B
  • JAZZ 6.1B
  • IPO Year
  • STVN 2021
  • JAZZ 2007
  • Fundamental
  • Price
  • STVN $21.55
  • JAZZ $110.80
  • Analyst Decision
  • STVN Buy
  • JAZZ Strong Buy
  • Analyst Count
  • STVN 6
  • JAZZ 13
  • Target Price
  • STVN $25.08
  • JAZZ $187.15
  • AVG Volume (30 Days)
  • STVN 334.9K
  • JAZZ 1.4M
  • Earning Date
  • STVN 05-08-2025
  • JAZZ 05-05-2025
  • Dividend Yield
  • STVN 0.27%
  • JAZZ N/A
  • EPS Growth
  • STVN N/A
  • JAZZ 41.75
  • EPS
  • STVN 0.45
  • JAZZ 8.65
  • Revenue
  • STVN $1,143,012,735.00
  • JAZZ $4,068,950,000.00
  • Revenue This Year
  • STVN $8.42
  • JAZZ $7.60
  • Revenue Next Year
  • STVN $10.36
  • JAZZ $3.43
  • P/E Ratio
  • STVN $47.85
  • JAZZ $12.82
  • Revenue Growth
  • STVN 1.72
  • JAZZ 6.12
  • 52 Week Low
  • STVN $16.56
  • JAZZ $95.49
  • 52 Week High
  • STVN $28.77
  • JAZZ $148.06
  • Technical
  • Relative Strength Index (RSI)
  • STVN 52.82
  • JAZZ 46.16
  • Support Level
  • STVN $21.13
  • JAZZ $103.51
  • Resistance Level
  • STVN $22.46
  • JAZZ $104.53
  • Average True Range (ATR)
  • STVN 1.25
  • JAZZ 5.88
  • MACD
  • STVN 0.07
  • JAZZ 1.19
  • Stochastic Oscillator
  • STVN 75.56
  • JAZZ 84.82

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: